PRIMERS: Polydopamine Radioimmunotherapy with Image-Guided Monitoring and Enhanced Release System

Shahinur Acter, Lindokuhle M. Ngema, Michèle Moreau, Debarghya China, Akila Viswanathan, Kai Ding, Yahya E. Choonara, Sayeda Yasmin‐Karim, Wilfred NgwaPharmaceutics 2024 · DOI

TL;DR

This paper introduces PRIMERS, a novel multifunctional nanoparticle system designed for image-guided radioimmunotherapy. PRIMERS combines the properties of polydopamine nanobowls with gadolinium for MRI contrast and the ability to load and release both chemotherapy (doxorubicin) and immunotherapy (anti-CD40) drugs, offering a promising approach to enhance cancer treatment efficacy while minimizing side effects.

What Problem Does This Paper Address?

Conventional cancer therapies like surgery, radiotherapy, chemotherapy, and immunotherapy, while effective to varying degrees, often suffer from limitations in therapeutic efficacy and significant toxicities. This leads to a global burden of cancer morbidity and mortality. The field is actively seeking advanced solutions, particularly multifunctional nanoparticles that can provide image guidance for precise treatment delivery, enhance therapeutic outcomes, and minimize damage to healthy tissues. Existing fiducial markers, used for image guidance in radiotherapy, are typically passive and lack the ability to deliver therapeutic agents or be actively monitored. This paper addresses the need for a single nanoplatform that can act as a sophisticated fiducial marker, provide real-time imaging contrast, and deliver multiple therapeutic agents in a controlled manner, specifically targeting the tumor microenvironment.

Methods

The core of the PRIMERS system is based on polydopamine (PDA) nanobowls, synthesized using an emulsion-induced interfacial anisotropic assembly method. This method allows for the creation of bowl-shaped mesoporous nanoparticles with controllable size and morphology.

Key functionalization steps include:

  • Gadolinium Coating: PDA nanobowls were coated with gadolinium chloride (GdCl₃) to impart Magnetic Resonance Imaging (MRI) contrast. This was achieved by adding GdCl₃ during the synthesis process, resulting in a thin layer of gadolinium on the nanobowl surface.
  • Drug Loading: The gadolinium-coated PDA nanobowls were loaded with:
  • Doxorubicin (DOX): An anti-cancer chemotherapy drug, loaded via π-π stacking interactions.
  • Anti-CD40: An immunotherapy drug (specifically, Alexa Fluor 700-tagged anti-human CD40), loaded through adsorption and covalent interaction.
  • Release Studies:
    • DOX Release: Investigated under acidic pH conditions (pH 5.6), mimicking the tumor microenvironment, using dialysis bags and PBS buffer.
  • Anti-CD40 Release: Studied in various pH environments and with/without radiation exposure.
  • Imaging and Characterization:
    • Transmission Electron Microscopy (TEM): Used to visualize the morphology and size of the nanobowls before and after functionalization and drug loading.
  • Dynamic Light Scattering (DLS) and Phase-Analysis Light Scattering (PALS): Employed to determine the average hydrodynamic size and zeta potential.
  • Fourier Transform Infrared (FTIR) Spectroscopy: Used for chemical characterization and confirmation of gadolinium coating.
  • MRI Imaging: Performed in vitro (agar gel phantom) and in vivo (mice models) using a 7T Bruker PET-MR Scanner to assess the contrast-enhancing capabilities of the gadolinium-coated nanobowls.
  • Confocal Microscopy: Used to confirm the loading of anti-CD40 into the nanobowls.
  • Cytotoxicity Assay: An MTT assay was conducted on TC-1 cells and Human Umbilical Vein Endothelial Cells (HUVEC) to evaluate the biocompatibility of the nanobowls.
  • In Vivo Studies: MRI imaging was performed on mice bearing subcutaneous tumors to monitor the presence and degradation of the nanobowls over time.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Multifunctionality in a Single Nanoparticle: The most significant insight is the successful integration of multiple functionalities – MRI contrast, chemotherapy delivery, and immunotherapy delivery – into a single nanoparticle system (PRIMERS). This moves beyond single-purpose nanoparticles towards a more holistic therapeutic approach.
  • pH- and Radiation-Triggered Drug Release: The ability of PRIMERS to release anti-CD40 in an acidic tumor microenvironment, with an enhanced release upon radiation exposure, is a critical finding. This suggests a sophisticated, context-aware drug delivery mechanism that can be activated by the tumor's specific conditions and the therapeutic intervention itself.
  • PDA Nanobowls as a Versatile Platform: The study reinforces the utility of polydopamine nanobowls as a highly adaptable platform for drug delivery and imaging. Their inherent properties, such as surface functionalization capabilities and mesoporous structure, make them ideal for accommodating various therapeutic agents and imaging agents.
  • Enhanced MRI Contrast for Image Guidance: The clear MRI contrast generated by the gadolinium-coated nanobowls, both in vitro and in vivo, highlights their potential as advanced fiducial markers. This allows for precise tracking of the nanobowls and, by extension, the targeted delivery of therapies.
  • Biocompatibility and Reduced Toxicity: The MTT assay results demonstrating no significant cytotoxicity of the gadolinium-coated nanobowls in TC-1 and HUVEC cells are crucial. This suggests that the PRIMERS system, even with its functionalization, maintains a favorable safety profile, a key requirement for clinical translation.

Key Results

  • MRI Contrast: Gadolinium-coated PDA nanobowls showed a significant positive contrast in T1-weighted MRI images, with signal intensity increasing with gadolinium concentration. This effect was observed both in phantom studies and in vivo in tumor-bearing mice.
  • Drug Loading Efficiency: The nanobowls demonstrated capacity for loading both doxorubicin and anti-CD40. While non-coated PDA nanobowls showed slightly higher DOX loading efficiency, the gadolinium-coated PRIMERS still exhibited good loading, suggesting the mesoporous structure and surface chemistry are conducive to drug adsorption.
  • Drug Release:
    • DOX release was observed to be favorable in acidic conditions (pH 5.6).
  • Anti-CD40 release was significantly enhanced in acidic environments and further boosted by radiation exposure in vitro.
  • In Vivo Monitoring: MRI imaging in mice showed a clear signal from the injected PRIMERS within the tumor, which gradually faded over time, indicating the degradation and clearance of the nanoparticles.
  • Cytotoxicity: MTT assays showed no significant cytotoxicity of the gadolinium-coated PDA nanobowls at concentrations up to 500 µg/mL, indicating good biocompatibility.

Limitations and Future Work

  • Drug Loading Efficiency Nuances: While PRIMERS showed good drug loading, the gadolinium coating slightly reduced DOX loading efficiency compared to non-coated nanobowls. Further optimization might be needed to maximize loading for specific drugs.
  • In Vivo Therapeutic Efficacy: The study focused on the preparation, characterization, and imaging capabilities of PRIMERS, along with in vitro release studies. While the potential for enhanced therapeutic efficacy is highlighted, direct in vivo therapeutic outcomes (e.g., tumor regression rates, survival benefits) were not presented.
  • Radiation Dose Optimization: While radiation was shown to enhance anti-CD40 release, the study noted that "no noticeable impact was observed with various doses of radiation." Further investigation into optimal radiation doses for maximizing release and therapeutic synergy could be beneficial.
  • Long-Term Biodegradation and Clearance: While the MRI signal faded, indicating clearance, a more detailed study on the long-term fate and potential accumulation of the nanoparticles and their components in various organs would be valuable for safety assessment.
  • Clinical Translation Challenges: The path from preclinical studies to clinical application involves numerous hurdles, including scalability of synthesis, regulatory approval, and detailed pharmacokinetic and pharmacodynamic studies in larger animal models.

Future work could focus on:

  • Conducting comprehensive in vivo studies to demonstrate the therapeutic efficacy of PRIMERS in combination with radiotherapy and immunotherapy.
  • Optimizing the formulation for specific cancer types and drug combinations.
  • Investigating the immune response generated by the anti-CD40 component in vivo.
  • Exploring alternative high-Z materials for enhanced imaging contrast or therapeutic effects.
  • Developing strategies for targeted delivery to specific tumor sites beyond intratumoral injection.

Summary updated

Abstract

<b>Background/Objectives:</b> To overcome the side effects of conventional cancer treatment, multifunctional nanoparticles with image-guidance properties are increasingly desired to obtain enhanced therapeutic efficacy without any toxicity of the treatment. Herein, we introduce the potential of Polydopamine Radioimmunotherapy with Image-guided Monitoring and Enhanced (drug) Release System (PRIMERS) to meet the challenges of currently used cancer therapy. <b>Methods:</b> The PDA nanobowls were synthesized using an emulsion-induced interfacial anisotropic assembly method followed by surface modification with high-Z material to obtained the final product PRIMERS. <b>Results:</b> The engineered multifunctional nanosystem "PRIMERS" could serve as fiducial markers with the potential for use in combination cancer therapy. By leveraging the advantages of the excellent surface functionalization capability of PDA, the anisotropic nanostructure (PDA nanobowls) has been successfully functionalized with gadolinium, which shows strong MRI contrast signal both in vitro in phantom and in vivo in animals. The results of anti-cancer drug loading and releasing efficiency of these functionalized nanobowls are presented. Moreover, the gadolinium-coated PDA nanobowls demonstrate the capacity for loading immunotherapy drugs (Anti-CD40) with activated release in acidic pH levels characteristic of the tumor microenvironment, with enhanced release following administration of radiation therapy in vitro. <b>Conclusions:</b> Overall, the results highlight the potential of this new technology for combining radiotherapy with activated image-guided drug delivery, which offers broad opportunities to overcome current challenges in cancer treatment.
BibTeX
@inproceedings{acter2024primers,
  author = {Shahinur Acter and Lindokuhle M. Ngema and Michèle Moreau and Debarghya China and Akila Viswanathan and Kai Ding and Yahya E. Choonara and Sayeda Yasmin‐Karim and Wilfred Ngwa},
  title = {{PRIMERS: Polydopamine Radioimmunotherapy with Image-Guided Monitoring and Enhanced Release System}},
  booktitle = {Pharmaceutics},
  year = {2024},
  doi = {10.3390/pharmaceutics16111481},
}
Figure